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Abstract
Background Peripheral arterial disease (PAD) is highly
prevalent among individuals of higher age or those with
one or more cardiovascular risk factors. Screening for PAD
is recommended, since it is often linked to atherothrombotic
manifestations in the coronary or carotid circulation and
associated with a substantial increase in all-cause and
cardiovascular mortality. We aimed to assess patients with
newly diagnosed, suspected and confirmed PAD in the
primary care setting with regards to clinical characteristics,
diagnostic and therapeutic management (including referral
to specialists), and medium-term outcomes.
Methods This was a multicentre, prospective, observational
cohort study with a cross-sectional and a longitudinal part.
A total of 2,781 general practitioners across Germany were
cluster randomised to document five consecutive patients
each in one of the strata: (1) patients with intermittent
claudication (IC) or other typical PAD-related complaints
(group A) or (2) patients >55 years of age with one or more
risk factors (group B) for PAD (current smoking, diabetes,
previous myocardial infection and/or previous stroke).
Patients with confirmed PAD will be followed up for
diagnostic procedures, therapy and vascular events over
18 months.
Results In group A, a total of 2,131 patients with suspected
PAD (80.1% confirmed, 75.9% with referral to specialists)
and in group B 9,921 patients were included (44.6%
confirmed, 54.6% referral). The ankle-brachial index was
calculated in 41.3% and 33.5% only. Mean age was
66.6 years (group A) and 68.4 years (group B), respective-
ly. Vascular risk factors were prevalent in both groups, in
particular smoking (group A 44.6%, group B 44.4%),
hypertension (73.2 and 78.1%), hypercholesterolaemia
(64.6 and 70.6%) and diabetes mellitus (41.7 and 60.6%).
Concomitant atherothrombotic morbidities were frequent in
both groups. In patients with the respective diseases,
antihypertensive, antidiabetic, lipid-lowering and antith-
rombotic therapies were prescribed in group A in 96.6,
96.0, 91.1 and 89.7% and in group B in 98.3, 97.4, 94.1
and 91.2%.
Conclusion The cross-sectional part of the study indicates a
substantial burden of disease in PAD patients in primary
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care. Treatment rates appear to have improved compared to
earlier surveys. In the follow-up period, outcomes of these
patients and their association with disease stages, guideline-
oriented treatment or patient compliance and disease-coping
strategies, among other factors, will be determined.
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Background
Atherosclerotic cardiovascular disease remains the most
common single cause of death in Germany and other
Western countries (Statistisches Bundesamt 2006). Its three
main manifestations comprise coronary heart disease
(CDH), cerebrovascular disease (CVD) and peripheral
arterial disease (PAD). The latter condition has been found
to be highly prevalent in the general population and in
primary care, respectively. For example, the getABI study
in 6,880 patients aged 65 years and above found asymp-
tomatic PAD as evidenced by a low ankle-brachial index
(ABI) in 12.1%, and symptomatic PAD in 8.7% of patients
(Diehm et al. 2004). Thus, only half of patients who present
with objective evidence of PAD have clinically significant
limb symptoms, such as walking impairment, intermittent
claudication, ischaemic rest pain or non-healing wounds
(Hirsch et al. 2006). The main medical problem of the PAD
patient is not losing the lower extremity due to amputation,
but rather to suffer a myocardial infarction or stroke (Heald
et al. 2006). In view of the high disease burden of PAD with
its associated risk of poor ischaemic outcomes, appropriate
screening and intervention measures—including aggressive
treatment of the common atherosclerotic risk factors—have
been suggested repeatedly (Belch et al. 2003; Hirsch et al.
2006; Norgren et al. 2007).
While the necessity of such measures is widely undis-
puted, the situation and management of PAD patients in
primary care has been less well investigated. It may well
differ between primary care setting across health care
systems and countries (Hirsch et al. 2001b; Khan et al.
2007), and therefore extrapolation may not be possible. The
primary care setting is of particular interest from a public
health perspective, because the general physician serves as
gatekeeper (Grumbach et al. 1999) with an important role
in the case finding for PAD, referral to specialists to
confirm or reject the suspected diagnosis and in the long-
term management of these risk patients.
Against this background, the Patient Care Evaluation-
Peripheral Arterial Disease (PACE-PAD) Study was initiated.
The present article describes the rationale, aims and methods
of the study and the key findings of the cross-sectional part.
Methods
Aims and study hypotheses
The primary aim of the study is the description of the
management (diagnostics and therapy) of patients with
newly diagnosed, suspected or confirmed PAD, with
particular focus on the interaction between general physi-
cian and specialist care, depending on patient-related
factors such as compliance with therapy and activity
(coping with disease).
Secondary study aims are the investigation of the
outcomes of guideline-oriented therapy on the incidence
of cardiovascular, cerebrovascular or peripheral vascular
events in patients with newly diagnosed PAD, depending
on patient-related factors such as compliance and activity.
The following hypotheses will be tested: The cumulative
incidence of cardiac, cerebrovascular and peripheral vascu-
lar events during the follow-up period is lower:
1. In PAD patients with guideline-oriented management
compared to PAD patients without such management
2. In PAD patients with high compliance compared with
those with low compliance
3. In PAD patients who are actively coping with their
disease compared with patients who do not
Design and study flow
PACE-PAD is a multicentre, observational, non-interventional
prospective study with pretest and pilot study periods, and in
the main study, a cross-sectional part (all patients) and a
longitudinal part with three visits over 18 months (for
confirmed PAD patients in Fontaine stage I-IV only, see
Fig. 1). Patients were assigned to two strata (symptomatic
patients and patients with risk factors, both with suspected
PAD).
A representative sample of ca. 43,500 physicians were
contacted (general physicians or internists in primary care)
throughout Germany. The “total design method” (Dillman
1991) for mail surveys was used with elements to ensure
high acceptance rates. Basic elements include: minimisation
of the burden on the respondent by designing question-
naires that are attractive in appearance and easy to
complete, printing mail questionnaires in booklet format,
placing personal questions at the end, creating a vertical
flow of questions and creating sections of questions based
on their content; constructing a persuasive letter and using
personalised communication; essential follow-up contacts
of non-respondents (Dillman 1991). The questionnaire was
pretested in terms of comprehensibility and feasibility with
12 randomly chosen physicians applying think aloud and
probing techniques.
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Physicians were assigned to one of two patient strata by
means of cluster randomisation using a computer-generated
randomisation list. They were requested to include consec-
utively up to five eligible patients in the assigned stratum.
The study was conducted according to the principles of
“good epidemiological practice” (Arbeitsgruppe Epidemio-
logische Methoden der Deutschen Arbeitsgemeinschaft
Epidemiologie, DAE). Protection of patient and centre data
was ensured. According to a statement of the legal
department of the University Duisburg-Essen, for this non-
interventional study a formal approval was not necessary.
Eligibility criteria
Patientswereeligible for inclusion ingroupAif theyhadnewly
occurring intermittent claudication (IC) or claudication-like
complaints with suspected PAD.
Patients with suspected PAD were eligible for inclusion
in group B if they were aged 55 years or above and had (1)
previous myocardial infarction and/or (2) previous ischae-
mic stroke and/or (3) manifest type 1 or type 2 diabetes
mellitus and/or (4) current smoking (for more than
10 years).
Patients were not eligible if they had PAD which had
been diagnosed earlier.
Cross-sectional part
At inclusion the initials, birth date and gender of the
patients were recorded. Further, type of insurance (private
or general) and participation at a disease management
program (diabetes mellitus type 1 or 2, coronary heart
disease or other) were noted. Besides weight, height,
systolic and diastolic blood pressure (method according to
physician discretion), presence of complaints possibly
associated with PAD (gluteal or leg pain when walking,
reduced walk distance, ulceration or problems with leg
wound healing), presence of risk factors for PAD (smoking,
type 1 or 2 diabetes, arterial hypertension, hypercholester-
olaemia and previously diagnosed carotid stenosis) were
recorded, as were previous ischaemic manifestations [tran-
sient ischaemic attack (TIA) or prolonged reversible
ischaemic neurological deficit (PRIND), stable or unstable
angina pectoris, including myocardial infarction] or inter-
ventions [percutaneous transluminal coronary angioplasty
(PTCA) with or without stenting, coronary artery bypass
surgery (CABG), carotid revascularisation or stenting].
The general health state of the patient was rated by the
physician on a 10-point numerical scale (1=extremely poor,
10=excellent). Similarly, compliance with therapy (1=
extremely poor, 10=excellent) as well as coping with
disease (1=passive, 10=active) were assessed.
The following diagnostic procedures for PAD were
recorded (by extremity, if applicable): leg pulse status at
arteria (a.) femoralis, a. tibialis posterior, a. dorsalis pedis
(normal, pathological, not assessed), auscultation of arter-
ies, Ratschow test, measurement of walking distance, tiptoe
exercise testing, Doppler-based measurement of the ABI,
PAD stage according to Fontaine stage (if confirmed: I:
asymptomatic, IIa: mild claudication, IIb: moderate-severe
claudication, III: ischaemic rest pain, IV: ulceration or
gangrene), alternatively differential diagnosis of PAD or
exclusion of PAD diagnosis in the office. Referrals were
recorded, too (angiology, vascular surgery, neurology,
orthopaedics, phlebology, radiology, other). In the case of
referral to a vascular specialist, his/her diagnoses (PAD yes/
no, Fontaine stage, ABI and therapy) were recorded, too.
The following therapeutic measures were recorded:
specific exercise, drug therapy [prostaglandins, rheologic
agents (pentoxifylline, naftidrofuryl) or other] and planned
vascular surgery (revascularisation, peripheral bypass sur-
gery). Further detailed assessment of risk factor manage-
ment was performed: smoking cessation, antithrombotic
therapy (aspirin, ticlopidine, clopidogrel, other), anticoagu-
lation (unfractionated heparins, low molecular weight
heparins, heparinoids, vitamin K antagonists, other), lipid-
lowering measures (diet, statins, fibrates, other), antihyper-
tensive treatment (salt restriction, diuretics, calcium channel
blockers, beta blockers, alpha1 blockers, AT1 receptor
Fig. 1 Study design
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antagonists, other), antidiabetic therapy (diet, insulin, oral
antidiabetic drugs) or other and unspecified measures used
for risk reduction.
Longitudinal study: endpoints at follow-up visits
The following endpoints will be recorded: myocardial
infarction, stroke or minor/major amputation due to PAD.
Statistics
The sample size was calculated based on the assumption
that the cumulative incidence of vascular events after
18 months is 6.8% in PAD patients with guideline-oriented
therapy vs 9.8% in other PAD patients. Guideline-oriented
therapy was defined by quality indicators that were
determined by a standardised questionnaire. A sample of
3,483 symptomatic patients (of whom at least 85% were
assumed to have diagnosed PAD) and of 20,485 patients
with risk factors (of whom at least 10% were assumed to
have diagnosed PAD) is required to obtain a power of 80%
at a significance level of 5%.
Using cross tables, frequency distributions and descriptive
statistics, the distributions of variables between the two patient
strata were compared. Additionally, a subgroup analysis of
patients aged ≥55 years was performed. Throughout all
analyses, a two-sided or the chi-square p value <0.05 (to
evaluate differences between proportions for two or more
than two groups) was considered to denote statistical
significance. All analyses were performed with SPSS version
13 for Windows (SPSS Inc, Chicago, IL, USA).
Findings of the cross-sectional study
Characteristics Table 1 provides an overview of demograph-
ic and clinical patient characteristics at inclusion.Mean patient
age was somewhat lower in group A compared to group B
(66.6 vs 68.4 years), as per definition in the latter group only
patients aged 55 years and above were eligible. Male patients
constituted about two thirds of the cohorts. While smoking
was recorded in both groups with equal frequency, the other
index risk factors current smoking, diabetes, hypertension and
hypercholesterolaemia were more prevalent in group B,
mostly with a long disease history. Previous ischaemic events
(myocardial infarctions, stroke etc.), related interventions and
current atherothrombotic manifestations (angina pectoris)
were noted substantially more frequently in group B, but
were also prevalent in group A.
Table 2 subdivides the patients in group A into those
aged below 55 years and those aged 55 years and above, in
order to enable direct comparison with the age-matched
group B. Compared to those patients aged ≥ 55 years, the
younger patients in group A were less frequently current
smokers, but included higher proportions of diabetic and
hypercholesterolaemic individuals.
Diagnostics In group A, 80.1% of all included patients
were finally assigned a PAD diagnosis and in group B
44.6% (Table 3). While the great majority of physicians
reported that they applied basic diagnostic measures such as
inspection, auscultation and leg pulse status (usually at
three levels and on both sides), walking distance (57.3% in
group A), tiptoe exercise testing (55.9% in group A) and
Ratschow test (33.7% in group A) were done less
frequently. The ABI was determined in 41.3 (group A)
and 33.5% (group B) only.
Referrals While in group A three quarters were also seen
by one or more specialists for further diagnostics or therapy,
the proportion was much lower (only 54.6%) in group B
(Table 4). If referred, patients in both groups were seen
mostly by angiologists or vascular specialists.
Health status, coping, compliance The majority of patients
were reported to be at an intermediate level of health status
(ca. 60% in level 4–7 on the 10-point scale; Table 5). About
a quarter of patients (27.8% in group A and 23.5% in
group B) were reported to be passive. Compliance with
diagnostics and therapy was predominantly intermediate or
high.
Management Table 6 shows the patient management for
diabetes, hypertension, hypercholesterolaemia and smoking
in both strata. General advice about smoking cessation in
current smokers and dietary advice in patients with elevated
blood cholesterol level was frequent in both groups.
Treatment rates with blood pressure-lowering therapy in
hypertensive patients were 96.6% in group A and 98.3% in
group B. Likewise, treatment rates were also similar in both
groups for diabetic patients (antidiabetic therapy in 96.0%
in group A and 97.4% in group B), as well as for lipid-
lowering therapy in hyperlipidaemic patients (91.1% in
group A and 94.1% in group B).
PAD The great majority of the PAD patients in both groups
received antithrombotics or anticoagulants (89.7% of group
A and 91.2% of group B; Table 7). Pain medication was
prescribed in a quarter of group A and group B patients.
While there was a substantially lower proportion of training
advice in group A (66.1 vs 71.4% in group B), in this group
more prescriptions of rheologic agents (35.0 vs 31.1% in
group B) and more planned vascular surgery interventions
(23.3 vs 20.6% of group B) were reported. Both groups
showed similar prescription prevalences of prostaglandins,
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Table 2 Vascular risk factors (age ≥ or <55 years)
Vascular risk factors Group A (age ≥55) (n=1,808) Group B (age ≥55) (n=9,921) p value Group A (age <55) (n=323)
None/1/2/3/4a 4.0/17.6/35.7/33.4/9.3 0.9/11.4/33.6/41.0/13.1 <0.05 5.3/27.2/26.9/29.7/10.8
Current smoking 39.4 (713) 44.4 (4,408) <0.05 73.7 (238)
>10 years 37.0 (669) 43.5 (4,318) <0.05 69.0 (223)
Diabetes mellitus 44.2 (800) 60.6 (6,010) <0.05 27.6 (89)
>10 years 22.1 (400) 50.4 (5,000) <0.05 8.4 (27)
Arterial hypertension 76.3 (1,379) 78.1 (7,751) 0.08 56.0 (181)
>10 years 51.4 (929) 57.2 (5,676) <0.05 20.4 (66)
Hypercholesterolaemia 66.1 (1,195) 70.6 (7,007) <0.05 56.3 (182)
>10 years 36.0 (651) 43.8 (4,346) <0.05 19.8 (64)
Carotid stenosis 9.2 (166) 8.7 (860) 0.47 4.0 (13)
Values indicate % (n)
a Carotid stenosis excluded
Table 1 Patient characteristics in the two strata at inclusion
Parameter Group A (n=2,131) Group B (n=9,921) p value
Age (years), mean SD 66.6±11.1 68.4±8.0 <0.05
<55 15.1 (323) 0 (0) <0.05
55–64 24.2 (515) 34.9 (3,464) <0.05
65–74 35.5 (756) 41.5 (4,113) <0.05
75–84 21.8 (465) 21.4 (2,123) 0.66
85+ 3.4 (72) 2.2 (221) <0.05
Males:females, % 63.9:36.1 67.5:32.5 <0.05
Body mass index 27.7±4.5 28.5±6.9 <0.05
Systolic and diastolic BP 140.4/82.6 139.1/81.2 <0.05
Complaints: yes 98.7 (2,103) 51.7 (4,576) <0.05
Vascular risk factors
None/1/2/3/4a 4.2/19.1/34.4/32.8/9.5 0.9/11.4/33.6/41.0/13.1 <0.05
Current smoking 44.6 (951) 44.4 (4,408) 0.89
>10 years 41.9 (892) 43.5 (4,318) <0.05
Diabetes mellitus 41.7 (889) 60.6 (6,010) <0.05
>10 years 20.0 (427) 50.4 (5,000) <0.05
Arterial hypertension 73.2 (1,560) 78.1 (7,751) <0.05
>10 years 46.7 (995) 57.2 (5,676) <0.05
Hypercholesterolaemia 64.6 (1,377) 70.6 (7,007) <0.05
>10 years 33.6 (715) 43.8 (4,346) <0.05
Carotid stenosis 8.4 (179) 8.7 (860) 0.73
Earlier ischaemic events
None/1/2/3/4/5/missing 61.2/21.5/11.5/4.5/0.9/0.2/0.2 38.5/23.4/25.6/10.1/2.0/0.4/0.0 <0.05
Cerebrovascular: any 13.7 (293) 24,0 (2,377) <0.05
TIA/PRIND 10.7 (228) 14.4 (1,433) <0.05
Ischaemic stroke 6.0 (127) 19.3 (1,913) <0.05
Coronary: any 31.3 (667) 47.4 (4,705) <0.05
Stable AP 26.4 (562) 34.9 (3,465) <0.05
Instable AP 6.7 (142) 12.2 (1,207) <0.05
Myocardial infarction 12.5 (267) 34.7 (3,445) <0.05
Coronary interventions
None 80.3 (1,711) 69.7 (6,917) <0.05
Percutaneous transluminal coronary angioplasty (PTCA) 11.4 (243) 19.1 (1,897) <0.05
Coronary artery bypass surgery (CABG) 6.9 (146) 12.5 (1,243) <0.05
Carotid surgery 2.9 (62) 2.9 (289) 0.99
Other 2.4 (52) 1.7 (165) <0.05
Values indicate % (n)
a Carotid stenosis excluded
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recommended bed rest, recommended posture of legs,
wound treatment and antibiotics.
Fontaine stages In group B, there were significantly more
asymptomatic PAD patients than in group A, while there
were significantly more PAD patients in group A in higher
stages (Table 8).
Table 3 Diagnostics to confirm or reject the PAD diagnosis in the
two strata
Frequency of
diagnostics
Group A
(n=2,131)
Group B
(n=9,921)
p value
Inspection 87.4 (1,863) 89.9 (8,921) <0.05
Pathological 32.7 (696) 17.6 (1,745) <0.05
Ambilateral pulse
status at 3 levelsa
86.0 (1,833) 83.7 (8,304) <0.05
Any level pathological 81.7 (1,740) 48.8 (4,843) <0.05
Auscultation 61.6 (1,313) 64.0 (6,349) <0.05
Pathological 26.5 (564) 16.1 (1,602) <0.05
Ratschow test 33.7 (719) 31.6 (3,136) 0.06
Pathological 21.7 (462) 12.6 (1,250) <0.05
Walking distance 57.3 (1,221) 44.2 (4,390) <0.05
Pathological 48.9 (1,041) 25.1 (2,487) <0.05
Tiptoe posture 55.9 (1,191) 51.1 (5,068) <0.05
Pathological 27.1 (577) 14.2 (1,410) <0.05
ABI measurement 41.3 (880) 33.5 (3,321) <0.05
≤0.9 29.0 (618) 17.0 (1,690) <0.05
Other 5.2 (111) 4.5 (444) 0.15
PAD diagnosedb 80.1 (1,706) 44.6 (4,423) <0.05
Values indicate % (n)
a A. femoralis, a. tibialis posterior, a. dorsalis pedis, both legs each
bWith specialist preference if applicable
Table 4 Referrals to specialists
Specialisation Group A
(n=2,131)
Group B
(n=9,921)
p value
Number: none
/1/2/3/4/5/6/7
24.1/45.7/
18.6/7.2/3.0/
0.7/0.4/0.3
45.4/32.3/
12.6/5.9/
2.2/1.2/0.3/0.1
<0.05
Angiology 41.2 (877) 28.2 (2,795) <0.05
Vascular
surgery
33.0 (703) 20.9 (2,069) <0.05
Neurology 10.0 (213) 10.2 (1,012) 0.81
Orthopaedics 11.5 (245) 9.4 (933) <0.05
Phlebology 6.0 (128) 5.6 (560) 0.51
Radiology 14.3 (305) 10.0 (997) <0.05
Other 8.4 (180) 8.2 (816) 0.73
Values indicate % (n)
Table 5 Health status, compliance and coping in the two strata
Parameter Group A (n=2,131) Group B (n=9,921) p value
General health status
1–3 12.5 (267) 11.2 (1,112) 0.08
4–7 60.7 (1,294) 60.4 (5,997) 0.83
8–10 26.3 (560) 28.1 (2,783) 0.10
Missing 0.5 (10) 0.3 (29) 0.21
Compliance
1–3 14.7 (314) 11.9 (1,182) <0.05
4–7 39.7 (845) 39.7 (3,936) 1.00
8–10 45.4 (968) 48.2 (4,780) <0.05
Missing 0.2 (4) 0.2 (23) 1.00
Coping
1–3 27.8 (592) 23.6 (2,336) <0.05
4–7 44.1 (939) 45.8 (4,544) 0.15
8–10 27.8 (593) 30.3 (3,009) <0.05
Missing 0.3 (7) 0.3 (32) 1.00
Values indicate % (n); 10-point scales with 0=worst and 10=best
value
Table 6 Prescription prevalences for diabetes, hypertension, hyper-
cholesterolaemia and smoking
Parameter Group A
(n=2,131)
Group B
(n=9,921)
p
value
Diabetes n=889 n=6,010
Recommended
diabetic diet
87.4 (777) 91.1 (5,478) <0.05
Insulin 32.8 (292) 37.4 (2,250) <0.05
Oral antidiabetic drugs 55.9 (497) 60.2 (3,619) <0.05
Other 5.2 (46) 4.5 (270) 0.35
Antidiabetics: any 96.0 (853) 97.4 (5,854) <0.05
Hypertension n=1,560 n=7,751
Recommended
sodium restriction
49.0 (765) 57.2 (4,431) <0.05
Diuretics 46.9 (731) 53.5 (4,147) <0.05
Calcium channel
blockers
32.4 (506) 32.4 (2,515) 1.00
Beta blockers 40.3 (628) 50.1 (3,881) <0.05
Alpha1 blockers 5.6 (87) 5.4 (416) 0.71
AT1 blockers 20.3 (317) 21.5 (1,667) 0.31
ACE inhibitor 54.7 (853) 60.2 (4,666) <0.05
Other 9.0 (141) 10.5 (813) 0.09
Antihypertensives: any 96.6 (1,507) 98.3 (7,616) <0.05
Hypercholesterolaemia n=1,377 n=7,007
Recommended
low-fat diet
77.7 (1,070) 84.1 (5,894) <0.05
Statins 72.3 (996) 75.9 (5,320) <0.05
Fibrates 4.6 (63) 4.9 (344) 0.63
Other 3.4 (47) 4.5 (314) 0.08
Lipid-lowering
therapy: any
91.1 (1,255) 94.1 (6,597) <0.05
Smoking n=951 n=4,408
Smoking stop
recommended
93.3 (887) 92.7 (4,088) 0.63
Values indicate % (n)
ACE angiotensin-converting enzyme
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Discussion
The present cross-sectional study provides detailed insights
into the characteristics, diagnostic procedures and thera-
peutic management of patients with suspected PAD on the
basis of symptoms (group A) or one or more cardiovascular
risk factors that are often associated with PAD (group B).
The study is open and non-controlled, which may lead to
bias. In contrast to randomised controlled trials, the present
study was performed in health service research. In this
context, a blinded design was not practical.
The suspicion of PAD on the basis of IC was verified
with further diagnostic procedures by the treating physician
in 80.1% of patients and in about half of the patients
(44.6%) with risk factors. This confirms that patients at
high risk can be easily identified on the basis of clinical
symptoms or by the presence of one or more of four easily
identifiable risk factors. A substantial proportion of patients
in both groups was referred to specialists for differential
diagnosis as indicated in the guidelines (e.g. exclusion of
spinal claudication, venous claudication, nerve root com-
pression or symptomatic Bakers’s cyst (Hirsch et al. 2006)).
Patients with previous CHD, CVD events or PAD had,
across vascular beds, remarkably consistent risk factors.
This finding is in line with the “Reduction of Atherothrom-
bosis for Continued Health (REACH)” registry (Bhatt et al.
2006) or the global observation of survivors of myocardial
infarction in the INTERHEART study (Yusuf et al. 2004).
Both groups in PACE-PAD showed high rates of
vascular risk factors and atherothrombotic manifestations;
the respective proportions were even higher in group B
owing to the inclusion criteria. It was interesting to note
that physicians in order to confirm the suspected PAD
diagnosis regularly applied the recommended elements of
physical examination (inspection, auscultation, pulse palpi-
tation at different levels) and did additional non-invasive
tests. However, the ABI, which is the most suitable non-
invasive screening test for PAD, was infrequently used to
confirm the diagnosis. Compared to angiography, an ABI
less than 0.9 is 90% sensitive and 98% specific for a
stenosis of 50% or more in leg arteries (Criqui et al. 1996;
Yao et al. 1969) and, among well-trained operators, the test-
retest reliability is excellent (Holland-Letz et al. 2007;
Kaiser et al. 1999). A large series of studies has confirmed
the prognostic value of a low ABI to predict future
cardiovascular and cerebrovascular events (Heald et al.
2006; Holland-Letz et al. 2007). While this diagnostic tool
is recommended in the major international and national
PAD guidelines, including those of the USA or Germany
(Diehm et al. 2001; Hirsch et al. 2006; Norgren et al. 2007),
it is still underused as PACE-PAD confirms. However, as
this study relies on self-reporting of the physicians,
reporting bias may have occurred.
Regarding management, the data in our study suggest
that treatment intensity in IC patients as well as in patients
with risk factors has improved. The current PAD guidelines
univocally agree that asymptomatic and symptomatic PAD
patients should be treated with the same intensity as other
manifestations of atherosclerosis, particularly coronary
heart disease. Besides the advice to stop smoking as the
central PAD risk factor, concomitant diabetes mellitus,
arterial hypertension and dyslipidaemia must be aggres-
sively treated (Hirsch and Gotto 2002; Hirsch et al. 2006;
Norgren et al. 2007). The benefit of antiplatelet therapy
[acetylic salicylic acid and clopidogrel; (1996)] has been
shown in many randomised controlled studies and a meta-
analysis of the Antithrombotic Trialists’ Collaboration
(Antithrombotic Trialists’ Collaboration 2002). Statins have
been shown to reduce coronary death in PAD patients
irrespective of their initial cholesterol value (Heart Protection
Table 7 Prescription prevalences for PAD
Parameter Group A
(n=1,706)
Group B
(n=4,423)
p
value
Antithrombotics: any 84.0 (1,433) 84.9 (3,755) 0.39
Anticoagulants: any 10.1 (172) 10.6 (469) 0.58
Antithrombotics or
anticoagulants
89.8 (1,532) 91.0 (4,023) 0.17
Prostaglandins 4.5 (76) 4.8 (214) 0.55
Rheologic agents 31.5 (537) 28.7 (1,271) <0.05
Planned vascular surgery
(revascularisation,
peripheral bypass
surgery)
23.3 (398) 20.6 (910) <0.05
Pain medication 23.7 (404) 23.1 (1,020) 0.61
Training 66.1 (1,127) 71.4 (3,157) <0.05
Recommended bed rest 4.9 (83) 5.6 (246) 0.31
Recommended
posture of legs
13.1 (224) 13.3 (589) 0.87
Wound treatment 11.5 (197) 11.6 (513) 1.00
Antibiotics 4.1 (70) 3.6 (160) 0.37
Values indicate % (n)
Table 8 Fontaine stages
Fontaine stages Group A
(n=1,706)
Group B
(n=4,423)
p
value
Missing/multiple stages 0.9 (16) 1.3 (58) 0.36
I (asymptomatic) 17.8 (304) 23.9 (1,055) <0.05
IIa (mild claudication) 35.5 (605) 34.2 (1,515) <0.05
IIb (moderate-severe
claudication)
33.1 (564) 29.7 (1,312) <0.05
III (ischaemic rest pain) 9.2 (157) 7.6 (336) <0.05
IV (ulceration or gangrene) 3.5 (60) 3.3 (147) <0.05
Values indicate % (n)
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Study Collaborative Group 2003), and similarly, the ACE
inhibitor ramipril (Yusuf et al. 2000) has been shown to
prevent coronary death in PAD patients with subclinical or
clinical disease (Ostergren et al. 2004). Applying these drug
treatments systematically to PAD patients would lead to a
25–30% mortality reduction (Feringa et al. 2006). The large
majority of patients in our study received recommendations
on how to improve lifestyle (smoking cessation, diet,
exercise), and compared to previous screening studies on
PAD, for example getABI in Germany (Pittrow et al. 2003),
or PARTNERS in the USA (Hirsch et al. 2001a), treatment
rates seem to have improved. The large contemporary
REACH registry reported in patients with manifest PAD
and the respective concomitant disease or condition drug
treatment rates of 92% for hypertension, 86% for diabetes,
70% for hyperlipidaemia and 82% for antiplatelet use (Bhatt
et al. 2006). While at first glance these rates appear
satisfactory, in that registry only a minority of patients were
at target goals for blood pressure, glucose, cholesterol, body
weight and non-use of tobacco (Bhatt et al. 2006).
The clinical health status of the majority of IC (Liles et
al. 2006) and of vascular risk patients is reduced, which is
also confirmed by our findings. Further, various disease-
coping strategies [such as “approach or avoidance” in
patients with CHD (van Elderen et al. 1999)] have been
described. The present study will provide an opportunity
to assess the association between these factors and PAD
outcomes.
Conclusions
A substantial number of PAD patients in general practice
are identified on the basis of IC symptoms or typical risk
factors. Increased use of the ABI would help to make the
diagnostic process more efficient. PAD patients carry a
substantial burden of disease (complaints, comorbidities).
Their outcomes will be followed prospectively in the
longitudinal part of this study.
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